Journal of Gastroenterology and Hepatology

Volume 25, Issue 10 p. 1692-1701

Attenuation of N-nitrosodiethylamine-induced liver fibrosis by high-molecular-weight fucoidan derived from Cladosiphon okamuranus

Kyoumi Nakazato,

Corresponding Author

Kyoumi Nakazato

School of Health Sciences, Faculty of Medicine, Gunma University, Showa-machi, Maebashi, Japan

Associate Kyoumi Nakazato, School of Health Sciences, Gunma University Faculty of Medicine, 3-39-15 Showa-machi, Maebashi, Gunma 371-8514, Japan. Email: [email protected]Search for more papers by this author

Hisashi Takada,

Hisashi Takada

School of Health Sciences, Faculty of Medicine, Gunma University, Showa-machi, Maebashi, Japan

Search for more papers by this author

Masahiko Iha,

Masahiko Iha

South Product Co., Ltd, Suzaki, Uruma City, Okinawa, Japan

Search for more papers by this author

Takeaki Nagamine,

Takeaki Nagamine

School of Health Sciences, Faculty of Medicine, Gunma University, Showa-machi, Maebashi, Japan

Search for more papers by this author

Kyoumi Nakazato,

Corresponding Author

Kyoumi Nakazato

School of Health Sciences, Faculty of Medicine, Gunma University, Showa-machi, Maebashi, Japan

Hisashi Takada,

Hisashi Takada

School of Health Sciences, Faculty of Medicine, Gunma University, Showa-machi, Maebashi, Japan

Search for more papers by this author

Masahiko Iha,

Masahiko Iha

South Product Co., Ltd, Suzaki, Uruma City, Okinawa, Japan

Search for more papers by this author

Takeaki Nagamine,

Takeaki Nagamine

School of Health Sciences, Faculty of Medicine, Gunma University, Showa-machi, Maebashi, Japan

Search for more papers by this author

First published: 18 November 2009

https://doi.org/10.1111/j.1440-1746.2009.06187.x

Citations: 32

Read the full text

About

PDF

Tools

Share a link

Email
Facebook
Twitter
LinkedIn
Reddit
Wechat

Abstract

Background and Aim: Liver fibrosis is closely associated with the progression of various chronic liver diseases. Fucoidan exhibits different biological properties such as anti-inflammatory, anti-oxidant and anti-fibrotic activities. The aim of this study was to determine whether oral fucoidan administration inhibits N-nitrosodiethylamine (DEN)-induced liver fibrosis.

Methods: Liver fibrosis was induced in rats by injecting DEN (50 mg/kg). Rats were given 2% of crude fucoidan solution or 2% of high-molecular-weight (HMW) fucoidan solution. They were divided into a crude fucoidan group, an HMW fucoidan group, a DEN alone group, a DEN + crude fucoidan group, a DEN + HMW fucoidan group and a control group.

Results: Liver fibrosis and hepatic hydroxyproline levels were significantly more decreased in the DEN + HMW fucoidan group than in the DEN-alone group. Anti-fibrogenesis was unremarkable in the DEN + crude fucoidan group. Hepatic messenger RNA levels and immunohistochemistry of transforming growth factor beta 1 were markedly increased by DEN. This increase was attenuated by HMW fucoidan. Hepatic chemokine ligand 12 expression was increased by DEN. This increase was suppressed by HMW fucoidan. HMW fucoidan significantly decreased the DEN-induced malondialdehyde levels. Also, fucoidan markedly increased metallothionein expression in the liver. Fucoidan was clearly observed in the liver by immunohistochemical staining in HMW fucoidan-treated rats, while it was faintly stained in the livers of crude fucoidan-treated rats.

Conclusion: These findings suggest that the HMW fucoidan treatment causes anti-fibrogenesis in DEN-induced liver cirrhosis through the downregulation of transforming growth factor beta 1 and chemokine ligand 12 expressions, and that scavenging lipid peroxidation is well-incorporated in the liver.

References

1 Friedman SL. Liver fibrosis: from bench to bedside. J. Hepatol. 2003; 38 (Suppl 1): S38–S53.
10.1016/S0168-8278(02)00429-4
PubMedWeb of Science®Google Scholar
2 Iredale JP. Cirrhosis: new research provided a basis for rational and targeted treatment. BMJ 2003; 327: 143–7.
10.1136/bmj.327.7407.143
PubMedWeb of Science®Google Scholar
3 Gines P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N. Engl. J. Med. 2004; 350: 1646–54.
10.1056/NEJMra035021
CASPubMedWeb of Science®Google Scholar
4 Bataller R, Brenner DA. Liver fibrosis. J. Clin. Invest. 2005; 115: 209–18.
10.1172/JCI24282
CASPubMedWeb of Science®Google Scholar
5 Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J. Cell. Mol. Med. 2006; 10: 76–99.
10.1111/j.1582-4934.2006.tb00292.x
CASPubMedWeb of Science®Google Scholar
6 Kurihara S, Yokoyama F, Inoue H et al. Sequential assessment of the intrahepatic expression of epidermal growth factor and transforming growth factor-β1 in hepatofibrogenesis of rat cirrhosis model. Int. J. Mol. Med. 2007; 19: 313–24.

Google Scholar
7 Preaux AM, Mallat A, Resenbaum J, Zafrani ES, Mavier P. Pentoxifylline inhibits growth and collagen synthesis of cultured human hepatic myofibroblast-like cells. Hepatology 1997; 26: 315–22.
10.1002/hep.510260210
CASPubMedWeb of Science®Google Scholar
8 Ueki T, Kaneda Y, Tsutsui H et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat. Med. 1999; 5: 226–30.
10.1038/5593
CASPubMedWeb of Science®Google Scholar
9 Marra F, Efsen E, Romanelli RG et al. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 2000; 119: 466–78.
10.1053/gast.2000.9365
CASPubMedWeb of Science®Google Scholar
10 Cho JJ, Hocher B, Herbst H et al. An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis. Gastroenterology 2000; 118: 1169–78.
10.1016/S0016-5085(00)70370-2
CASPubMedWeb of Science®Google Scholar
11 Galli A, Crabb DW, Ceni E et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 2002; 122: 1924–40.
10.1053/gast.2002.33666
CASPubMedWeb of Science®Google Scholar
12 Houglum K, Venkataramani A, Lyche K, Chojkier M. A pilot study of the effect of D-α-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology 1997; 113: 1069–73.
10.1053/gast.1997.v113.pm9322499
CASPubMedWeb of Science®Google Scholar
13 Shimizu I, Ma YR, Mizobuchi Y et al. Effects of Sho-saiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats. Hepatology 1999; 29: 149–60.
10.1002/hep.510290108
CASPubMedWeb of Science®Google Scholar
14 Vendemiale G, Grattagliano I, Caruso ML et al. Increased oxidative stress in dimethylnitrosamine-induced liver fibrosis in rats: effect of N-acetylcysteine and interferon-α. Toxicol. Appl. Pharmacol. 2001; 175: 130–9.
10.1006/taap.2001.9234
CASPubMedWeb of Science®Google Scholar
15 Nakamura T, Sakata R, Ueno T, Sata M, Ueno H. Inhibition of transforming growth factor beta prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats. Hepatology 2000; 32: 247–55.
10.1053/jhep.2000.9109
CASPubMedWeb of Science®Google Scholar
16 Bruck R, Genina O, Aeed H et al. Halofuginone to prevent and treat thioacetamide- induced liver fibrosis in rats. Hepatology 2001; 33: 379–86.
10.1053/jhep.2001.21408
CASPubMedWeb of Science®Google Scholar
17 George J, Roulot D, Koteliansky VE, Bissell DM. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc. Natl. Acad. Sci. USA 1999; 96: 12719–24.
10.1073/pnas.96.22.12719
CASPubMedWeb of Science®Google Scholar
18 Kondou H, Mushiaki S, Etani Y, Miyoshi Y, Michigami T, Ozono K. A blocking peptide for transforming growth factor-beta 1 activation prevents hepatic fibrosis in vivo. J. Hepatol. 2003; 39: 742–8.
10.1016/S0168-8278(03)00377-5
CASPubMedWeb of Science®Google Scholar
19 De Gouville AC, Boullay V, Krysa G et al. Inhibition of TGF-beta signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis. Br. J. Pharmacol. 2005; 145: 166–77.
10.1038/sj.bjp.0706172
CASPubMedWeb of Science®Google Scholar
20 Chizhov AO, Dell A, Morris HR et al. A study of fucoidan from the brown seaweed Chorda filum. Carbohydr. Res. 1999; 320: 108–19.
10.1016/S0008-6215(99)00148-2
CASPubMedWeb of Science®Google Scholar
21 Ruperez P, Ahrazem O, Leal JA. Potential antioxidant capacity of sulfated polysaccharides from the edible marine brown seaweed Fucus vesiculosus. J. Agric. Food. Chem. 2002; 50: 840–5.
10.1021/jf010908o
CASPubMedWeb of Science®Google Scholar
22 Berteau O, Mulloy B. Sulfated fucans, fresh perspectives: structures, functions, and biological properties of sulfated fucans and an overview of enzymes active toward this class. Glycobiology 2003; 13: R20–40.
10.1093/glycob/cwg058
Web of Science®Google Scholar
23 Zhao X, Xue C, Li Z, Cai Y, Liu H, Qi H. Antioxidant and hepatoprotective activities of low molecular weight sulfated polysaccharide from Laminaria japonica. J. Appl. Phycol. 2004; 16: 111–15.
10.1023/B:JAPH.0000044822.10744.59
CASWeb of Science®Google Scholar
24 Veena CK, Josephine A, Preetha AP, Rajesh NG, Varalakshmi P. Mitochondrial dysfunction in an animal model of hyperoxaluria: a prophylactic approach with fucoidan. Eur. J. Pharmacol. 2008; 579: 330–6.
10.1016/j.ejphar.2007.09.044
CASPubMedWeb of Science®Google Scholar
25 Boisson-Vidal C, Zemani F, Caligiuri G et al. Neoangiogenesis induced by progenitor endothelial cells: effect of fucoidan from marine algae. Cardiovasc. Hematol. Agents Med. Chem. 2007; 5: 67–77.
10.2174/187152507779315778
CASPubMedGoogle Scholar
26 Kang KS, Kim ID, Kwon RH, Lee JY, Kang JS, Ha BJ. The Effects of Fucoidan Extracts on CCl4-Induced Liver Injury. Arch. Pharm. Res. 2008; 31: 622–7.
10.1007/s12272-001-1203-8
CASPubMedWeb of Science®Google Scholar
27 Wang J, Zhang Q, Zhang Z, Li Z. Antioxidant activity of sulfated polysaccharide fractions extracted from Laminaria japonica. Int. J. Biol. Macromol. 2008; 42: 127–32.
10.1016/j.ijbiomac.2007.10.003
CASPubMedWeb of Science®Google Scholar
28 Hayashi S, Itoh A, Isoda K, Kondoh M, Kawase M, Yagi K. Fucoidan partly prevents CCL4-induced liver fibrosis. Eur. J. Parmacol. 2008; 580: 380–4.
10.1016/j.ejphar.2007.11.015
CASPubMedWeb of Science®Google Scholar
29 Cumashi A, Ushakova NA, Preobrazhenskaya ME et al. A comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds. Glycobiology 2007; 12: 1–42.

Google Scholar
30 Chabut D, Fischer AM, Colliec-Jouault S et al. Low molecular weight fucoidan and heparin enhance the basic fibroblast growth factor-induced tube formation of endothelial cells through heparan sulfated-dependent alpha6 over expression. Mol. Pharmacol. 2003; 64: 696–702.
10.1124/mol.64.3.696
CASPubMedWeb of Science®Google Scholar
31 Luyt CE, Meddahi-Pelle A, Ho-Tin-Noe B et al. Low-molecular-weight fucoidan promotes therapeutic revascularization in a rat model of critical hindlimb ischemia. J. Pharmacol. Exp. Ther. 2003; 305: 24–30.
10.1124/jpet.102.046144
CASPubMedWeb of Science®Google Scholar
32 Zemani F, Benisvy D, Galy-Fauroux I et al. Low-molecular-weight fucoidan enhances the proangiogenic phenotype of endothelial progenitor cells. Biochem. Pharnacol. 2005; 70: 1167–75.
10.1016/j.bcp.2005.07.014
CASPubMedWeb of Science®Google Scholar
33 Matsubara K, Xue C, Zhao X, Mori M, Sugawara T, Hirata T. Effects of middle molecular weight fucoidans on in vitro and in vivo angiogenesis of endothelial cells. Int. J. Mol. Med. 2005; 15: 695–9.

CASPubMedWeb of Science®Google Scholar
34 Soeda S, Kozako T, Iwata K, Shimeno H. Over sulfated fucoidan inhibits the basic fibroblast growth factor-induced tube formations by human umbilical vein endothelial cells: its possible mechanism of action. Biochem. Biophys. Acta 2000; 1497: 127–34.
10.1016/S0167-4889(00)00052-5
CASPubMedWeb of Science®Google Scholar
35 Nagamine T, Takada H, Kusakabe K et al. Intracellular changes of metal elements by fucoidan extracted from Brawn Seaweed. Biol. Trace Elem. Res. 2008; 124: 60–9.
10.1007/s12011-008-8123-x
CASPubMedWeb of Science®Google Scholar
36 Nakazato K, Nakajima K, Kusakabe T, Suzuki K, Nagamine T. Immunohistochemical staining with newly developed metallothionein fragment antibodies against NH2-terminal, middle-regional and COOH-terminal peptides in rabbits. Pathol. Int. 2008; 58: 765–70.
10.1111/j.1440-1827.2008.02308.x
CASPubMedWeb of Science®Google Scholar
37 Nagaoka M, Shibata H, Kimura-Takagi I et al. Structural study of fucoidan from Cladosiphon okamuranus Tokida. Glycoconj. J. 1999; 16: 19–26.
10.1023/A:1006945618657
CASPubMedWeb of Science®Google Scholar
38 Ellis AJ, Curry VA, Powell EK, Cawston TE. The prevention of collagen breakdown in bovine nasal cartilage by TIMP, TIMP-2 and a low molecular weight synthetic inhibitor. Biochem. Biophys. Res. Commun. 1994; 201: 94–101.
10.1006/bbrc.1994.1673
CASPubMedWeb of Science®Google Scholar
39 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976; 72: 48–54.

Google Scholar
40 Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 1979; 95: 351–8.
10.1016/0003-2697(79)90738-3
CASPubMedWeb of Science®Google Scholar
41 Bissel DM, Roulot D, George J. Transforming growth factor beta and liver. Hepatology 2001; 34: 859–67.
10.1053/jhep.2001.28457
CASPubMedWeb of Science®Google Scholar
42 McCaffrey TA, Falcone DJ, Vicente D, Du B, Consigli S, Borth W. Protection of transforming growth factor-beta 1 activity by heparin and fucoidan. J. Cell. Physiol. 1994; 159: 51–9.
10.1002/jcp.1041590108
CASPubMedWeb of Science®Google Scholar
43 O'Leary R, Rerek M, Wood EJ. Fucoidan modulates the effect of transforming growth factor (TGF)-beta1 on fibroblast proliferation and wound repopulation in vitro models of dermal wound repair. Biol. Pharm. Bull. 2004; 27: 266–70.
10.1248/bpb.27.266
CASPubMedWeb of Science®Google Scholar
44 Murdoch C, Finn A. Chemokine receptors and their role in infectious diseases. Blood 2000; 95: 3023–43.

Google Scholar
45 Vlahakis SR, Villasis-Keever A, Gomez T, Vanegas M, Viahakis N, Paya CV. G protein-coupled chemokine receptors induce both survival and apoptotic signaling pathways. J. Immunol. 2002; 169: 5546–54.
10.4049/jimmunol.169.10.5546
CASPubMedWeb of Science®Google Scholar
46 Scotton CJ, Chambers RC. Molecular targets in pulmonary fibrosis. Chest 2007; 132: 1311–21.
10.1378/chest.06-2568
PubMedWeb of Science®Google Scholar
47 Wald O, Pappo O, Safadi R et al. Involvement of the CXCL12/CXCR4 pathway in the advanced liver disease that is associated with hepatitis C virus or hepatitis B virus. Eur. J. Immunol. 2004; 34: 1164–74.
10.1002/eji.200324441
CASPubMedWeb of Science®Google Scholar
48 Mavier P, Martin N, Couchie D, Preaux AM, Laperche Y, Zafraui ES. Expression of stromal cell-derived factor-1 and of its receptor CXCR4 in liver regeneration from oval cells in rat. Am. J. Pathol. 2004; 165: 1969–77.
10.1016/S0002-9440(10)63248-8
CASPubMedWeb of Science®Google Scholar
49 Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs 2001; 61: 2035–63.
10.2165/00003495-200161140-00003
CASPubMedWeb of Science®Google Scholar

Citing Literature

Volume25, Issue10

October 2010

Pages 1692-1701

Attenuation of N-nitrosodiethylamine-induced liver fibrosis by high-molecular-weight fucoidan derived from Cladosiphon okamuranus

Abstract

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Attenuation of N-nitrosodiethylamine-induced liver fibrosis by high-molecular-weight fucoidan derived from Cladosiphon okamuranus

Abstract

References

Citing Literature

References

Related

Information